At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Folfox plus Bevacizumab and reolysin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.
In Brief
A Phase 2 clinical trial evaluating Folfox plus Bevacizumab and reolysin and Folfox plus Bevacizumab for Colorectal Cancer. Completed, enrolled 109 participants across 10 sites.
Detailed Summary
The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesCanada
CollaboratorsOncolytics Biotech
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartOct 2012
Primary CompletionJan 2017
Study CompletionSep 2018
TodayJul 2026
First PostedJun 19, 2012
Enrollment StartOct 26, 2012
Primary CompletionJan 18, 2017
Study CompletionSep 12, 2018
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 14.0 years ago
Interventions
Folfox plus Bevacizumab and reolysindrug
FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
Folfox plus Bevacizumabdrug
FOLFOX6/bevacizumab given every 14 days.